Li Xu, Jessi R Prentice, Raul Velez-Montoya, Alina Sinha, Mark R Barakat, Ashwin Gupta, Robert Lowenthal, Arshad M Khanani, Peter K Kaiser, Jeffrey S Heier, Anthony Jones, Joshua L Morgenstern, Anne Strong Caldwell, Niklaus Mueller, Hugo Quiroz-Mercado, Michael Huvard, Jeffrey L Olson, Ramesh Bhatt, Ramanath Bhandari
OBJECTIVE: To investigate preclinical data regarding the efficacy and biocompatibility of a bispecific protein, RO-101, with effects on VEGF-A and angiopoietin-2 (Ang-2) for use in retinal diseases. DESIGN: Experimental study. SUBJECTS: Brown Norway rats and New Zealand White Cross rabbits. METHODS: Preclinical study data of RO-101 in terms of target-specific enzyme-linked immunosorbent assay binding affinity to VEGF-A and Ang-2, vitreous half-life, inhibition of target-receptor interaction, laser choroidal neovascular membrane animal model, human umbilical vein endothelial cell migration, and biocompatibility was obtained...
2024: Ophthalmol Sci